New hope for lung cancer patients after targeted therapy fails
NCT ID NCT07158840
First seen Oct 31, 2025 · Last updated May 04, 2026 · Updated 19 times
Summary
This study tests a drug called AK112 in 60 adults with advanced non-squamous non-small cell lung cancer who have specific genetic changes and whose previous targeted therapy (TKI) stopped working. The goal is to see if AK112 can shrink tumors or slow the disease. Participants must be 18-75 years old, in good general health, and have a life expectancy of at least 3 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.